These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31233269)

  • 1. Effects of Message Framing on Patients' Perceptions and Willingness to Change to a Biosimilar in a Hypothetical Drug Switch.
    Gasteiger C; Jones ASK; Kleinstäuber M; Lobo M; Horne R; Dalbeth N; Petrie KJ
    Arthritis Care Res (Hoboken); 2020 Sep; 72(9):1323-1330. PubMed ID: 31233269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients' beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch.
    Gasteiger C; Lobo M; Dalbeth N; Petrie KJ
    Rheumatol Int; 2021 Jan; 41(1):163-171. PubMed ID: 32300866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Biosimilar, so it looks alike, but what does it mean?" A qualitative study of Danish patients' perceptions of biosimilars.
    Varma M; Almarsdóttir AB; Druedahl LC
    Basic Clin Pharmacol Toxicol; 2022 May; 130(5):581-591. PubMed ID: 35261174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
    Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
    Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars.
    Rezk MF; Pieper B
    Adv Ther; 2018 Jun; 35(6):749-753. PubMed ID: 29873005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. US rheumatologists' beliefs and knowledge about biosimilars: a survey.
    Gibofsky A; McCabe D
    Rheumatology (Oxford); 2021 Feb; 60(2):896-901. PubMed ID: 33146388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients' information and perspectives on biosimilars in rheumatology: A French nation-wide survey.
    Frantzen L; Cohen JD; Tropé S; Beck M; Munos A; Sittler MA; Diebolt R; Metzler I; Sordet C
    Joint Bone Spine; 2019 Jul; 86(4):491-496. PubMed ID: 30659920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.
    Schulze-Koops H; Skapenko A
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv30-iv48. PubMed ID: 28903543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4).
    Scherlinger M; Langlois E; Germain V; Schaeverbeke T
    Semin Arthritis Rheum; 2019 Apr; 48(5):927-932. PubMed ID: 30093238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a clinical pharmacist in a multidisciplinary consultation on the switch to a biosimilar for inflammatory rheumatic diseases.
    Levivien C; Bottois C; López Medina C; Dumas S; Hubert J; Belo S; Roux C; Conort O; Dougados M
    Joint Bone Spine; 2022 May; 89(3):105322. PubMed ID: 34896303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study.
    Tweehuysen L; Huiskes VJB; van den Bemt BJF; Vriezekolk JE; Teerenstra S; van den Hoogen FHJ; van den Ende CH; den Broeder AA
    Arthritis Rheumatol; 2018 Sep; 70(9):1408-1418. PubMed ID: 29609207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The process defines the product: what really matters in biosimilar design and production?
    Vulto AG; Jaquez OA
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv14-iv29. PubMed ID: 28903544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical specialists' attitudes to prescribing biosimilars.
    Hemmington A; Dalbeth N; Jarrett P; Fraser AG; Broom R; Browett P; Petrie KJ
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):570-577. PubMed ID: 28233367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare professionals' perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study.
    Aladul MI; Fitzpatrick RW; Chapman SR
    BMJ Open; 2018 Nov; 8(11):e023603. PubMed ID: 30455389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
    Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.
    Moots R; Azevedo V; Coindreau JL; Dörner T; Mahgoub E; Mysler E; Scheinberg M; Marshall L
    Curr Rheumatol Rep; 2017 Jun; 19(6):37. PubMed ID: 28623625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis.
    Renton WD; Leveret H; Guly C; Smee H; Leveret J; Ramanan AV
    Pediatr Rheumatol Online J; 2019 Oct; 17(1):67. PubMed ID: 31585539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bio-what? Medical companions' perceptions towards biosimilars and information needs in rheumatology.
    Gasteiger C; Scholz U; Petrie KJ; Dalbeth N
    Rheumatol Int; 2022 Nov; 42(11):1993-2002. PubMed ID: 34705051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to biosimilars in the treatment of rheumatic diseases.
    Yoo DH; Choe JY; Shim SC; Suh CH
    Expert Rev Clin Immunol; 2018 Jul; 14(7):557-571. PubMed ID: 29914272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.